During the last decade, Cell-Penetrating Peptides<\/a> (CPPs) have been investigated for\u00a0their ability to overcome the cell membrane barrier for the intracellular or transcellular\u00a0delivery of cargoes, such as many low molecular weight drugs, imaging agents, peptides,\u00a0oligonucleotides, proteins and colloidal carriers such as liposomes and polymeric\u00a0nanoparticles. Their ability to cross biological plasma membranes, especially in a\u00a0non-disruptive way without apparent toxicity is highly desired for increasing drug\u00a0bioavailability. Attempts have been made to extract related structural information\u00a0that would predict mechanism of the uptake process of the transport peptides. For\u00a0example, positive charges in side chains of Arg\/Lys, presence of Trp or Phe residues in\u00a0certain positions, amphiphilicity of the peptide, and length of the polypeptide chain have\u00a0been proposed as important factors determining cellular uptake. However, despite\u00a0numerous studies carried out in the field, the mechanism of uptake of CPPs is still not\u00a0clarified. Therefore, rational design of novel transport peptides, such as comparison of\u00a0positive-charges-containing CPPs and neutralized form CPPs, sequence of cationic amino\u00a0acid residues and the role of clustering of net positive charges will be necessary for\u00a0successful application of CPPs in research and therapy.<\/p>\n

Application of CPPs<\/a>.<\/b><\/strong>
\n<\/b><\/strong>A major obstacle in the development of new therapeutic agents is the low\u00a0bioavailability of hydrophilic substances. It is well known that, drugs that bind to\u00a0intracellular targets must penetrate the lipid bilayer membrane surrounding the cell in order to exert their effect. Fortunately, a relatively new research area that addresses\u00a0this problem by introducing novel transport peptides, which attract many researchers in\u00a0this field, has emerged. Most researchers look at the delivery of many therapeutic\u00a0molecules by various CPPs, and their potential therapeutic application in a wide range of\u00a0areas. These peptides predominantly have a positive net charge and\/or an amphipathic\u00a0nature, but can otherwise have very different characteristics and with the ability to cross\u00a0the plasma membranes of mammalian cells in an apparently energy- and\u00a0receptor-independent fashion compared to receptor-mediated carriers. This group of\u00a0peptides, also sometimes called protein transduction domains (PTDs), is here referred to\u00a0as cell-penetrating peptides (CPPs). As mentioned previously, the limited therapeutic\u00a0value of polypeptides and oligonucleotides in biomedical research and as pharmaceutical\u00a0substances is due to their low biomembrane permeability and their relatively rapid\u00a0degradation. So people expect that the possibility to manipulate intracellular biological\u00a0targets would increase if large-sized hydrophobic molecules could be addressed\u00a0intracellularly, without severe limitation on amounts inherent to the necessity to cross\u00a0membrane lipid bilayers. Thus, the discovery that CPPs translocate across the plasma\u00a0membrane of live cells and permit intracellular transport of cargoes, such as conjugated\u00a0peptides, proteins, oligonucleotides and nanoparticles, although in a still not clarified way,\u00a0has opened new possibilities and proposed new hopes in biomedical research and therapy.<\/p>\n

Although there is much debate over the mechanism by which this “protein\u00a0transduction” occurs, the ability of CPPs to translocate rapidly into cells is being\u00a0exploited to deliver a broad range of therapeutics in a variety of situations and biological\u00a0systems. The ability CPPs to deliver different cargoes in a relatively efficient and\u00a0non-invasive manner has implications as far reaching as drug delivery, gene transfer,\u00a0DNA vaccination and beyond. Although many questions remain to be answered and\u00a0limitations on the use of CPPs exist, it is clear that this emerging technology has much to\u00a0offer in a clinical setting.<\/p>\n

 <\/p>\n

Reference:<\/p>\n

Ling Ren. COMPARISON OF CELLULAR UPTAKE OF\u00a0ARGININE-RICH CELL-PENETRATING PEPTIDES<\/p>\n","protected":false},"excerpt":{"rendered":"

During the last decade, Cell-Penetrating Peptides (CPPs) have been investigated for\u00a0their ability to overcome the cell membrane barrier for the intracellular or transcellular\u00a0delivery of cargoes, such as many low molecular …<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[75],"tags":[81],"_links":{"self":[{"href":"https:\/\/www.creative-peptides.com\/blog\/wp-json\/wp\/v2\/posts\/439"}],"collection":[{"href":"https:\/\/www.creative-peptides.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.creative-peptides.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.creative-peptides.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.creative-peptides.com\/blog\/wp-json\/wp\/v2\/comments?post=439"}],"version-history":[{"count":2,"href":"https:\/\/www.creative-peptides.com\/blog\/wp-json\/wp\/v2\/posts\/439\/revisions"}],"predecessor-version":[{"id":441,"href":"https:\/\/www.creative-peptides.com\/blog\/wp-json\/wp\/v2\/posts\/439\/revisions\/441"}],"wp:attachment":[{"href":"https:\/\/www.creative-peptides.com\/blog\/wp-json\/wp\/v2\/media?parent=439"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.creative-peptides.com\/blog\/wp-json\/wp\/v2\/categories?post=439"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.creative-peptides.com\/blog\/wp-json\/wp\/v2\/tags?post=439"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}